Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
This article was originally published in PharmAsia News
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
You may also be interested in...
Aslan Pharmaceuticals received approval for a Phase I clinical trial of a rheumatoid arthritis DHODH inhibitor by Singapore’s Health Sciences Authority and will work with CRO Quintiles at Changi General Hospital.
ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup
ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.
AstraZeneca pays $20 million up front to license Hutchison’s Phase I-ready compound in another sign that the U.K. pharma has its eyes set firmly on China.